Gut microbiota in human systemic lupus erythematosus and a mouse model of lupus
Patients with established cardiovascular disease should receive a pharmacological treatment intensification with an agent that has demonstrated benefit in cardiovascular safety studies: In patients with pre-existing atherosclerotic cardiovascular disease (ASCVD), a GLP-1 receptor agonist, or SGLT-2 inhibitor with characterized cardiovascular safety should be used
How will we manage demand as awareness and interest continue to grow
Advantages of MT-1 Long-lasting skin pigmentation Greater selectivity for MC1R May improve photoprotection Lower risk of off-target effects than Melanotan 2 Advantages of MT-2 Faster skin pigmentation Higher receptor potency May reduce appetite May increase sexual arousal Potential Side Effects MT-1 and MT-2 may cause side effects, including nausea, facial flushing, headache, and changes in skin pigmentation
The result is a vicious cycle where declining NAD+ leads to worse metabolic function, which can lead to weight gain, which increases NNMT activity further
Only medical-grade protocols